Background: FMS-like tyrosine kinase 3 (FLT3) is a commonly mutated gene in acute
myeloid leukemia. As a receptor tyrosine kinase (RTK), FLT3 plays a role in the proliferation …

Background Acute myeloid leukaemia (AML) is an aggressive blood cancer. In
approximately 30% of the cases, driver mutations in the FLT3 gene are identified. FLT3 …

Mutations in the receptor tyrosine kinase FLT3 occur frequently in patients with acute
myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Small molecules that …

FLT3 and dual Aurora B/FLT3 inhibitors have shown relevance in the search for promising
new anticancer compounds, mainly for acute myeloid leukemia (AML). This study was …

Aberrant activation of FMS-like tyrosine receptor kinase 3 (FLT3) is implicated in the
pathogenesis of acute myeloid leukemia (AML) in 20–30% of patients. In this study we …

Tyrosine kinase domain (TKD) mutations contribute to acquired resistance to FMS-like
tyrosine kinase 3 (FLT3) inhibitors used to treat FLT3-mutant acute myeloid leukemia (AML) …

The receptor tyrosine kinase FLT-3 is frequently mutated in acute myeloid leukemia;
however, current small molecule inhibitors suffer from limited efficacy in the clinic …

Fms-like tyrosine kinase 3 (FLT3) is implicated in the pathogenesis of acute myeloid
leukemia (AML). FLT3-activating internal tandem duplication (ITD) mutations are found in …

Overexpression and frequent mutations in FMS-like tyrosine kinase-3 (FLT3) are considered
risk factors for severe acute myeloid leukemia (AML). Hyperactive FLT3 induces premature …

The hematopoietic class III receptor tyrosine kinase (RTK) Flt3 (Flk2, STK1) has recently
received much attention as a potential drug target. Activation of Flt3 by different types of …